Trial Profile

A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jan 2025 Results presented in an AIM ImmunoTech media release
23 Jan 2025 According to an AIM ImmunoTech media release, today announced that the final Clinical Study Results for the ''Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions'' was posted yesterday to ClinicalTrials.gov
15 Jan 2025 According to an AIM ImmunoTech media release, Final approved study results to be published on Clinicaltrials.gov in Q1 of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com